Clearside Biomedical Inc [NASDAQ: CLSD] plunged by -$0.01 during the normal trading session on while it closed the day at $0.86.
Clearside Biomedical Inc stock has also loss -1.81% of its value over the past 7 days. However, CLSD stock has declined by -1.93% in the 3 months of the year. Over the past six months meanwhile, it has lost -16.21% and lost -9.16% year-on date.
The market cap for CLSD stock reached $67.06 million, with 77.27 million shares outstanding and 61.36 million shares in the current float. Compared to the average trading volume of 177.18K shares, CLSD reached a trading volume of 129302 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Clearside Biomedical Inc [CLSD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLSD shares is $5.43 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLSD stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Chardan Capital Markets have made an estimate for Clearside Biomedical Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 21, 2024. While these analysts kept the previous recommendation, Oppenheimer raised their target price to Outperform. The new note on the price target was released on June 25, 2024, representing the official price target for Clearside Biomedical Inc stock. Previously, the target price had yet another drop from $19 to $9, while Wedbush kept a Outperform rating on CLSD stock.
The Average True Range (ATR) for Clearside Biomedical Inc is set at 0.06, with the Price to Sales ratio for CLSD stock in the period of the last 12 months amounting to 17.84.
CLSD stock trade performance evaluation
Clearside Biomedical Inc [CLSD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.81. With this latest performance, CLSD shares gained by 1.71% in over the last four-week period, additionally sinking by -16.21% over the last 6 months – not to mention a drop of -42.08% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLSD stock in for the last two-week period is set at 49.54, with the RSI for the last a single of trading hit 49.41, and the three-weeks RSI is set at 49.00 for Clearside Biomedical Inc [CLSD]. The present Moving Average for the last 50 days of trading for this stock 0.8803, while it was recorded at 0.8679 for the last single week of trading, and 1.0091 for the last 200 days.
Clearside Biomedical Inc [CLSD]: An insightful look at the core fundamentals
Clearside Biomedical Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.19 and a Current Ratio set at 3.19.
Earnings per share (EPS) analysis for Clearside Biomedical Inc [CLSD] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLSD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Clearside Biomedical Inc go to -2.08%.
Clearside Biomedical Inc [CLSD]: Institutional Ownership
There are presently around $14.32%, or 16.46%% of CLSD stock, in the hands of institutional investors. The top three institutional holders of CLSD stocks are: VANGUARD GROUP INC with ownership of 2.84 million shares, which is approximately 3.8003%. ROSALIND ADVISORS, INC., holding 2.59 million shares of the stock with an approximate value of $$3.37 million in CLSD stocks shares; and ROSALIND ADVISORS, INC., currently with $$2.78 million in CLSD stock with ownership which is approximately 2.8582%.
